Novo Nordisk Reports Phase II Data for Zenagamtide in Diabetes

Why It Matters

The results position zenagamtide as the first dual GLP‑1/amylin agonist, potentially expanding treatment options for diabetes and obesity and strengthening Novo Nordisk’s pipeline against competitors.

Key Takeaways

• Phase II trial showed –1.71% HbA1c change at 40 mg dose
• Body weight fell 14.6% versus 2.1% with placebo
• Over 89% of participants reached HbA1c below 7%
• Adverse events were mild, mainly gastrointestinal
• Phase III enrollment slated for H2 2026

Pulse Analysis

The diabetes therapeutics landscape has been reshaped over the past decade by GLP‑1 receptor agonists, yet clinicians still grapple with patients who need deeper glycemic control and concurrent weight management. Novo Nordisk’s zenagamtide, a single‑molecule combo of GLP‑1 and amylin receptor activity, aims to fill that gap by leveraging complementary mechanisms: GLP‑1 improves insulin secretion and satiety, while amylin curbs post‑prandial glucose spikes and reduces appetite. This dual action reflects a broader industry trend toward multi‑target agents that can simplify regimens and enhance outcomes for the growing population of adults with type 2 diabetes and obesity.

In the Phase II dose‑finding study, zenagamtide produced a mean HbA1c reduction of 1.71 percentage points at the highest dose, eclipsing the modest 0.14‑point change seen with placebo and rivaling the efficacy of Novo’s own semaglutide‑based products. Equally striking was the 14.6% average weight loss—far exceeding the 2.1% placebo figure and comparable to the weight reductions reported for CagriSema, Novo’s recent GLP‑1/amylin candidate that outperformed Ozempic in Phase III. Moreover, more than 89% of participants achieved the clinically important HbA1c target of <7%, and time‑in‑range exceeded 90% at the top dose, underscoring robust glucose stability. Safety signals remained predictable, with mild gastrointestinal events mirroring the class profile of existing GLP‑1 therapies.

If Phase III confirms these findings, zenagamtide could become a first‑in‑class option that consolidates two proven pathways into one weekly injection, offering physicians a powerful tool to address both hyperglycemia and excess weight. Such a breakthrough would reinforce Novo Nordisk’s dominance in the high‑growth GLP‑1 market, pressure rivals to accelerate their own combination strategies, and potentially reshape payer formularies toward agents that deliver dual metabolic benefits. The upcoming H2 2026 trial will be closely watched by investors and clinicians alike, as its outcomes may set a new benchmark for integrated diabetes‑obesity treatment.